Better understanding of the molecular cause of these rare genetic conditions has led to successful treatment with targeted drug therapy such as MEK-inhibitors (e.g., Noonan syndrome, Neurofibromatosis type 1). Here, MAP2K7 is linked to Noonan syndrome.